AI is revolutionizing the pharma supply chain by automating manual tasks, monitoring risks and providing predictive insights.

Italy’s Axxam and Molecular Health have partnered to identify and validate new therapeutic targets in drug development.

Digital innovations such as ePRO and eCOA are streamlining clinical trials, boosting participant engagement, and improving data quality.

Redwire Corporation has secured a contract from Aspera Biomedicines to carry out space-based research on a cancer treatment.

Agenus has signed $141m partnership agreements with Zydus Lifesciences and its subsidiaries to enhance clinical developments ...

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

In this issue: assessing the regulators' role as AI in clinical trials evolves, the potential for a newborn screening refresh ...

Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.

The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

The FDA set a PDUFA date in late 2025 as ziftomenib led to significant disease response in patients with common subtype of ...

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...